Merck is sounding decidedly upbeat about the recent data on MK-0524, an experimental therapy for reducing flushing in patients with dyslipidemia. Flushing is an uncomfortable and common side effect associated with niacin and one of the primary reasons why patients stop taking the therapy. Dyslipidemia is a condition that disrupts the quantity of lipids in the blood. Merck is currently in Phase III with MK-0524A, a combination of MK-0524 and extended release niacin.
- here's the AFX report [1] on the trial data
Links:
[1] http://www.forbes.com/markets/feeds/afx/2006/11/15/afx3177107.html